Antitrypanosomal and Antileishmanial Activities of Flavonoids and Their Analogues: In Vitro, In Vivo, Structure-Activity Relationship, and Quantitative Structure-Activity Relationship Studies
ABSTRACT
Trypanosomiasis and leishmaniasis are important parasitic diseases affecting millions of people in Africa, Asia, and South America. In a previous study, we identified several flavonoid glycosides as antiprotozoal principles from a Turkish plant. Here we surveyed a large set of flavonoid aglycones and glycosides, as well as a panel of other related compounds of phenolic and phenylpropanoid nature, for their in vitro activities against Trypanosoma brucei rhodesiense , Trypanosoma cruzi , and Leishmania donovani . The cytotoxicities of more than 100 compounds for mammalian L6 cells were also assessed and compared to their antiparasitic activities. Several compounds were investigated in vivo for their antileishmanial and antitrypanosomal efficacies in mouse models. Overall, the best in vitro trypanocidal activity for T. brucei rhodesiense was exerted by 7,8-dihydroxyflavone (50% inhibitory concentration [IC 50 ], 68 ng/ml), followed by 3-hydroxyflavone, rhamnetin, and 7,8,3′,4′-tetrahydroxyflavone (IC 50 s, 0.5 μg/ml) and catechol (IC 50 , 0.8 μg/ml). The activity against T. cruzi was moderate, and only chrysin dimethylether and 3-hydroxydaidzein had IC 50 s less than 5.0 μg/ml. The majority of the metabolites tested possessed remarkable leishmanicidal potential. Fisetin, 3-hydroxyflavone, luteolin, and quercetin were the most potent, giving IC 50 s of 0.6, 0.7, 0.8, and 1.0 μg/ml, respectively. 7,8-Dihydroxyflavone and quercetin appeared to ameliorate parasitic infections in mouse models. Generally, the test compounds lacked cytotoxicity in vitro and in vivo. By screening a large number of flavonoids and analogues, we were able to establish some general trends with respect to the structure-activity relationship, but it was not possible to draw clear and detailed quantitative structure-activity relationships for any of the bioactivities by two different approaches. However, our results can help in directing the rational design of 7,8-dihydroxyflavone and quercetin derivatives as potent and effective antiprotozoal agents.
Top-30
Journals
|
5
10
15
20
|
|
|
Molecules
20 publications, 5.19%
|
|
|
Journal of Natural Products
10 publications, 2.6%
|
|
|
Journal of Ethnopharmacology
9 publications, 2.34%
|
|
|
Natural Product Research
9 publications, 2.34%
|
|
|
Experimental Parasitology
7 publications, 1.82%
|
|
|
European Journal of Medicinal Chemistry
7 publications, 1.82%
|
|
|
Fitoterapia
7 publications, 1.82%
|
|
|
Parasitology Research
5 publications, 1.3%
|
|
|
PLoS Neglected Tropical Diseases
5 publications, 1.3%
|
|
|
Parasitology International
5 publications, 1.3%
|
|
|
Biomedicine and Pharmacotherapy
5 publications, 1.3%
|
|
|
Antimicrobial Agents and Chemotherapy
5 publications, 1.3%
|
|
|
Journal of Parasitic Diseases
4 publications, 1.04%
|
|
|
Natural Product Communications
4 publications, 1.04%
|
|
|
Scientific Reports
4 publications, 1.04%
|
|
|
Revista Brasileira de Farmacognosia
4 publications, 1.04%
|
|
|
South African Journal of Botany
4 publications, 1.04%
|
|
|
Studies in Natural Products Chemistry
4 publications, 1.04%
|
|
|
Planta Medica
4 publications, 1.04%
|
|
|
F1000Research
3 publications, 0.78%
|
|
|
International Journal of Molecular Sciences
3 publications, 0.78%
|
|
|
Plants
3 publications, 0.78%
|
|
|
Frontiers in Pharmacology
3 publications, 0.78%
|
|
|
Acta Parasitologica
3 publications, 0.78%
|
|
|
Medicinal Chemistry Research
3 publications, 0.78%
|
|
|
PLoS ONE
3 publications, 0.78%
|
|
|
Bioorganic and Medicinal Chemistry Letters
3 publications, 0.78%
|
|
|
Phytomedicine
3 publications, 0.78%
|
|
|
Acta Tropica
3 publications, 0.78%
|
|
|
5
10
15
20
|
Publishers
|
20
40
60
80
100
120
|
|
|
Elsevier
110 publications, 28.57%
|
|
|
Springer Nature
50 publications, 12.99%
|
|
|
MDPI
43 publications, 11.17%
|
|
|
Taylor & Francis
31 publications, 8.05%
|
|
|
American Chemical Society (ACS)
23 publications, 5.97%
|
|
|
Wiley
19 publications, 4.94%
|
|
|
Royal Society of Chemistry (RSC)
11 publications, 2.86%
|
|
|
Hindawi Limited
11 publications, 2.86%
|
|
|
Public Library of Science (PLoS)
8 publications, 2.08%
|
|
|
Bentham Science Publishers Ltd.
6 publications, 1.56%
|
|
|
Frontiers Media S.A.
6 publications, 1.56%
|
|
|
Georg Thieme Verlag KG
6 publications, 1.56%
|
|
|
SAGE
5 publications, 1.3%
|
|
|
American Society for Microbiology
5 publications, 1.3%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
4 publications, 1.04%
|
|
|
F1000 Research
3 publications, 0.78%
|
|
|
King Saud University
3 publications, 0.78%
|
|
|
Cambridge University Press
2 publications, 0.52%
|
|
|
Academic Journals
2 publications, 0.52%
|
|
|
Brieflands
2 publications, 0.52%
|
|
|
Cold Spring Harbor Laboratory
2 publications, 0.52%
|
|
|
EDP Sciences
1 publication, 0.26%
|
|
|
PeerJ
1 publication, 0.26%
|
|
|
Pharmaceutical Society of Japan
1 publication, 0.26%
|
|
|
The Royal Society
1 publication, 0.26%
|
|
|
IOP Publishing
1 publication, 0.26%
|
|
|
Taiwan Institute of Chemical Engineers
1 publication, 0.26%
|
|
|
Pleiades Publishing
1 publication, 0.26%
|
|
|
Science Alert
1 publication, 0.26%
|
|
|
20
40
60
80
100
120
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.